Bioton S.A. Asset Resilience Ratio

Latest as of December 2017: 0.01%

Bioton S.A. asset resilience ratio. Bioton S.A. (BIO) has an Asset Resilience Ratio of 0.01% as of December 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bioton S.A. debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

zł163.00K
≈ $44.86K USD Cash + Short-term Investments

Total Assets

zł1.14 Billion
≈ $314.29 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Bioton S.A. (2005–2019)

Asset resilience ratio of Bioton S.A. from 2005 to 2019. This chart shows how Bioton S.A.'s Asset Resilience Ratio has changed over time. See Bioton S.A. (BIO) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Bioton S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Bioton S.A. asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents zł0.00 0%
Short-term Investments zł163.00K 0.01%
Total Liquid Assets zł163.00K 0.01%

Asset Resilience Insights

  • Limited Liquidity: Bioton S.A. maintains only 0.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Bioton S.A. Industry Peers by Asset Resilience Ratio

Compare Bioton S.A.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Bioton S.A. Asset Resilience Ratio by Year (2005–2019)

Bioton S.A. asset resilience ratio by year from 2005 to 2019. The table below shows the annual Asset Resilience Ratio data for Bioton S.A..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2019-12-31 0.20% zł1.72 Million
≈ $474.19K
zł881.42 Million
≈ $242.58 Million
-2.28pp
2016-12-31 2.47% zł32.02 Million
≈ $8.81 Million
zł1.30 Billion
≈ $356.45 Million
+1.92pp
2015-12-31 0.56% zł6.95 Million
≈ $1.91 Million
zł1.25 Billion
≈ $344.03 Million
+0.53pp
2013-12-31 0.03% zł491.00K
≈ $135.13K
zł1.89 Billion
≈ $520.37 Million
-0.71pp
2011-12-31 0.73% zł14.83 Million
≈ $4.08 Million
zł2.02 Billion
≈ $557.19 Million
-0.87pp
2010-12-31 1.61% zł25.42 Million
≈ $7.00 Million
zł1.58 Billion
≈ $435.30 Million
+0.72pp
2009-12-31 0.89% zł14.32 Million
≈ $3.94 Million
zł1.60 Billion
≈ $441.67 Million
-1.35pp
2008-12-31 2.24% zł46.35 Million
≈ $12.76 Million
zł2.06 Billion
≈ $568.26 Million
+0.87pp
2007-12-31 1.37% zł21.23 Million
≈ $5.84 Million
zł1.55 Billion
≈ $425.52 Million
-5.08pp
2006-12-31 6.46% zł64.01 Million
≈ $17.62 Million
zł991.63 Million
≈ $272.91 Million
+6.00pp
2005-12-31 0.46% zł1.65 Million
≈ $452.73K
zł358.12 Million
≈ $98.56 Million
--
pp = percentage points

About Bioton S.A.

WAR:BIO Poland Biotechnology
Market Cap
$80.35 Million
zł291.94 Million PLN
Market Cap Rank
#19853 Global
#161 in Poland
Share Price
zł3.40
Change (1 day)
-2.86%
52-Week Range
zł3.40 - zł4.39
All Time High
zł15.39
About

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more